<DOC>
	<DOCNO>NCT00962520</DOCNO>
	<brief_summary>This study phase II trial erlotinib combination chemoradiation patient resect stage I/II adenocarcinoma pancreas candidate adjuvant chemoradiation . Eligible patient receive adjuvant treatment erlotinib 100 mg plus Capecitabine 800 mg/m2 mouth twice daily ( PO BID ) ( 5 day on/2 day regimen ) External Beam Radiation Therapy ( EBRT ) dose 50.4 Gy 28 fraction pancreatectomy ( dose capecitabine erlotinib amend consider toxicity profile first 6 patient ) . Approximately 4-8 week conclusion chemoradiation , recommend patient continue treatment 4 cycle gemcitabine 1000 mg/m2 day 1 , 8 , 15 every 28 day plus daily erlotinib 100 mg .</brief_summary>
	<brief_title>Tarceva With Chemoradiation Adjuvant Chemotherapy Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Resection stage I/II pancreatic adenocarcinoma pancreas ( R0/R1 ) candidate receive postoperative adjuvant chemoradiation . R2 ( macroscopic resection ) base surgeon operative note exclude study . 2 . Aged 18 year old . 3 . ECOG performance status &lt; 1 . 4 . The effect Erlotinib Capecitabine develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 5 . Patients must normal organ marrow function define : leukocyte &gt; = 3,000/μl absolute neutrophil count &gt; = 1,500/μl platelet &gt; = 100,000/μl total bilirubin &lt; = 2 mg/dL AST ( SGOT ) /ALT ( SGPT ) &lt; = 5 X institutional upper limit normal creatinine &lt; = 2 mg/dL aPTT &lt; 40 second , PT &lt; 2 second ULN . 6 . Provision write informed consent 7 . Patients must work knowledge English order complete quality life questionnaire . Patients meet requirement exempt QoL assessment , remain eligible component study . 1 . Known severe hypersensitivity Erlotinib excipient product . Hypersensitivity Capecitabine , doxifluridine , 5FU . 2 . Other coexist malignancy malignancy diagnose within last 5 year , exception basal cell carcinoma , noninvasive early stage bladder cancer ( &lt; T1 ) , cervical cancer situ . 3 . Uncontrolled , intercurrent illness include ( limited ) ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 4 . Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital , St John 's Wort . Careful monitor PT/INR must do patient take Warfarin . 5 . Incomplete heal previous oncologic major surgery . 6 . Gastrointestinal tract disease result inability take oral medication . 7 . Pregnant woman exclude study Erlotinib epidermal growth factor inhibitor potential teratogenic abortifacient effect base data suggest EGFR expression important normal organ development . Because unknown potential risk adverse event nurse infant secondary treatment mother Erlotinib , breastfeed discontinue mother treated Erlotinib . Capecitabine also potentially teratogenic metabolite find breast milk . 8 . Patients known AIDS HIVpositive antiretroviral therapy exclude since patient ' immune deficiency increase risk lethal infection treat marrowsuppressive therapy , interaction Erlotinib antiretroviral therapy unknown . If patient know risk factor HIV test base discretion treat oncologist . 9 . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude ) . 10 . Previous radiation abdomen . 11 . Previous chemotherapy pancreatic cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>resectable</keyword>
	<keyword>Tarceva</keyword>
</DOC>